Tarsus Pharmaceuticals Inc
TARS
Market Cap$1.29B
Close$
$-23.61
157% downside
Current Fair Value
157% downsideOvervalued by 157% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.29 Billion |
|---|---|
| Enterprise Value | $1.11 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-4.62 |
| Beta | 1.08 |
| Outstanding Shares | 37,823,233 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -8.54 |
|---|---|
| PEG | 21.26 |
| Price to Sales | 13.82 |
| Price to Book Ratio | 4.61 |
| Enterprise Value to Revenue | 8.59 |
| Enterprise Value to EBIT | -7.9 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Tarsus Pharmaceuticals Inc
20 employeesTarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address a num...